Gemcitabine in locally advanced and/or m
โ
Hans von der Maase
๐
Article
๐
2000
๐
Elsevier Science
๐
English
โ 90 KB
Gemcitabine is a promising new drug in patients with locally advanced and/or metastatic transitional cell carcinoma of the urothelium. The drug has been tested as a single-agent in one phase I study and four phase II studies. Gemcitabine was administered on days 1, 8 and 15 every 28 days with a dose